

**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

LEUCOFELIGEN FeLV/RCP lyophilisate and suspension for suspension for injection for cats

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Per dose of 1 ml:

*Lyophilisate:*

### Active substances:

Live attenuated feline calicivirus (strain F9)	$10^{4.6}$ – $10^{6.1}$ CCID <sub>50</sub> *
Live attenuated feline viral rhinotracheitis virus (strain F2)	$10^{5.0}$ – $10^{6.6}$ CCID <sub>50</sub> *
Live attenuated feline panleucopenia virus (strain LR 72)	$10^{3.7}$ – $10^{4.5}$ CCID <sub>50</sub> *

\* Cell culture infectious dose 50%.

*Suspension:*

### Active substance:

Minimum quantity of purified p45 FeLV-envelope antigen	102 µg
--	--------

### Adjuvants:

3% aluminium hydroxide gel expressed as mg Al <sup>3+</sup>	1 mg
Purified extract of <i>Quillaja saponaria</i>	10 µg

### Excipients:

Qualitative composition of excipients and other constituents
<b>Lyophilisate:</b>
Gelatin
Potassium hydroxide
Lactose monohydrate
Glutamic acid
Potassium dihydrogen phosphate
Dipotassium phosphate
Water for injections
Sodium chloride
Disodium phosphate
<b>Suspension:</b>
Sodium chloride
Disodium phosphate
Potassium dihydrogen phosphate
Water for injections

Aluminium hydroxide gel
-------------------------

**Visual appearance:**

Lyophilisate: White color.

Suspension: Opalescent liquid.

### **3. CLINICAL INFORMATION**

#### **3.1 Target species**

Cats.

#### **3.2 Indications for use for each target species**

For active immunisation of cats from eight weeks of age against:

- feline calicivirosis to reduce clinical signs,
- feline viral rhinotracheitis to reduce clinical signs and viral excretion,
- feline panleucopenia to prevent leucopenia and to reduce clinical signs,
- feline leukaemia to prevent persistent viraemia and clinical signs of the related disease.

Onset of immunity:

- 3 weeks after the first injection of primary vaccination for the calicivirus component
- 3 weeks after the primary vaccination for the panleucopenia and leukaemia components,
- 4 weeks after the primary vaccination for the rhinotracheitis virus component.

Duration of immunity:

After the primary vaccination course, the duration of immunity lasts for one year for all components.

Following a first booster vaccination one year after the primary vaccination course, a duration of immunity of 3 years has been demonstrated for the leukaemia component.

#### **3.3 Contraindications**

None.

#### **3.4 Special warnings**

Vaccinate healthy animals only.

Maternally derived antibodies, especially those against feline panleucopenia virus, can negatively influence the immune response to vaccination.

#### **3.5 Special precautions for use**

Special precautions for safe use in the target species:

De-worming at least 10 days prior to vaccination is recommended.

Only feline leukaemia virus (FeLV) negative cats should be vaccinated. Therefore, a test for presence of FeLV before vaccination is recommended.

The feline calicivirus and feline panleucopenia virus vaccine strains can spread. It has been demonstrated that this spread did not cause adverse reactions on non-vaccinated cats.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

### 3.6 Adverse events

Cats:

Common (1 to 10 animals / 100 animals treated):	Injection site reaction <sup>1</sup> , Injection site swelling <sup>1</sup> , Injection site oedema <sup>1</sup> , Injection site nodule <sup>1</sup> .  Hyperthermia <sup>2,3</sup> , Apathy <sup>3</sup>  Digestive tract disorder <sup>3</sup> .
Rare (1 to 10 animals / 10,000 animals treated):	Injection site pain <sup>4, 5</sup> ,  Sneezing <sup>5</sup> ,  Conjunctivitis <sup>5</sup> .
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Anaphylaxis <sup>6</sup> .  Febrile limping syndrome reactions <sup>7</sup> .

<sup>1</sup>A moderate and transient local reaction ( $\leq 2$  cm) is observed after the first injection and resolves spontaneously within 3 to 4 weeks at the most. After the second injection, and subsequent administrations, this reaction is markedly reduced.

<sup>2</sup>Lasting 1 to 4 days.

<sup>3</sup>Transient signs.

<sup>4</sup>At palpation.

<sup>5</sup>This resolves without any treatment.

<sup>6</sup>In case of anaphylactic shock, appropriate symptomatic treatment should be administered.

<sup>7</sup>May occur very rarely in kittens, as reported in the literature after the use of any vaccine containing a Feline Calicivirus component.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

Do not use in pregnant cats.

The use is not recommended during lactation.

### 3.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

### **3.9 Administration routes and dosage**

Subcutaneous use.

Reconstitute one dose of lyophilisate with one dose of suspension, shake gently and administer immediately.

Administer subcutaneously one dose (1ml) of the veterinary medicinal product according to the following regimen of vaccination.

#### Primary vaccination:

- first injection in kittens from 8 weeks of age
- second injection 3 or 4 weeks later.

Maternally derived antibodies, especially those against feline panleucopenia virus, can negatively influence the immune response to vaccination. In such cases where maternally derived antibodies are expected, a third injection may be appropriate from 15 weeks of age.

#### Re-vaccinations:

Following a first booster vaccination one year after the primary vaccination course, subsequent vaccinations can be performed at intervals of three years for the leukaemia component.

In this case, since annual revaccination is required for calicivirus, rhinotracheitis virus and panleucopenia virus components, a single dose of FELIGEN RCP can be used annually.

The vaccine can be used as a booster for kittens or cats previously vaccinated with FELIGEN RCP and LEUCOGEN separately.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

No adverse reactions were observed after an overdose administration (10 doses of lyophilisate and 2 doses of suspension) of the veterinary medicinal product other than those mentioned in section 3.6 except local reactions that can last longer (from 5 to 6 weeks at the most).

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Not applicable.

## **4. IMMUNOLOGICAL INFORMATION**

### **4.1 ATCvet code: QI06AH07**

Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia.

The vaccine contains the purified p45 FeLV-envelope antigen, obtained by genetic recombination of the *E. coli* strain. The antigenic suspension is adjuvanted with an aluminium hydroxide gel and with a purified extract of *Quillaja saponaria*.

For the leukaemia component, protection against persistent viraemia is observed in 73% of cats 3 weeks after their first vaccine injection.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf life after reconstitution according to directions: use immediately.

### **5.3 Special precautions for storage**

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze.

Protect from light.

### **5.4 Nature and composition of immediate packaging**

#### Lyophilisate:

A type I glass vial containing one dose of freeze-dried attenuated live viral components with a butyl elastomer stopper.

#### Suspension:

A type I glass vial containing one dose (1 ml) of the adjuvanted liquid vaccine, with a 13 mm-diameter butyl elastomer stopper and set with an aluminium capsule.

Plastic or cardboard box of 10 lyophilisate vials and 10 suspension vials.

Plastic or cardboard box of 50 lyophilisate vials and 50 suspension vials.

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

VIRBAC

## **7. MARKETING AUTHORISATION NUMBER(S)**

EU/2/09/097/001–002

**8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 25/06/2009.

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

{MM/YYYY}

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

## **ANNEX II**

### **OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

None.



**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE****Box of 10 or 50 lyophilisate vials and 10 or 50 suspension vials****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

LEUCOFELIGEN FeLV/RCP lyophilisate and suspension for suspension for injection

**2. STATEMENT OF ACTIVE SUBSTANCES**

Per dose of 1 ml:

Lyophilisate:**Active substances:**

Live attenuated feline calicivirus (strain F9)	$10^{4.6}-10^{6.1}$ CCID <sub>50</sub> *
Live attenuated feline viral rhinotracheitis virus (strain F2)	$10^{5.0}-10^{6.6}$ CCID <sub>50</sub> *
Live attenuated feline panleucopenia virus (strain LR 72)	$10^{3.7}-10^{4.5}$ CCID <sub>50</sub> *

\* Cell culture infectious dose 50%.

Suspension:**Active substance:**

Minimum quantity of purified p45 FeLV-envelope antigen:	102 µg
---	--------

**3. PACKAGE SIZE**

10 x 1 dose

50 x 1 dose

**4. TARGET SPECIES**

Cats

**5. INDICATIONS****6. ROUTES OF ADMINISTRATION**

Subcutaneous use

**7. WITHDRAWAL PERIODS****8. EXPIRY DATE**

Exp. {mm/yyyy}

Once reconstituted use immediately.

**9. SPECIAL STORAGE PRECAUTIONS**

Store and transport refrigerated.  
Do not freeze.  
Protect from light.

**10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

VIRBAC

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/09/097/001  
EU/2/09/097/002

**15. BATCH NUMBER**

Lot {number}

<b>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b> <b>LYOPHILISATE VIAL</b>
---

<b>1. NAME OF THE VETERINARY MEDICINAL PRODUCT</b>
--

LEUCOFELIGEN FeLV/RCP

<b>2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES</b>
---

RCP  
1 dose

<b>3. BATCH NUMBER</b>
------------------------

Lot {number}

<b>4. EXPIRY DATE</b>
-----------------------

Exp. {mm/yyyy}

<b>MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS</b> <b>SUSPENSION VIAL</b>
---

<b>1. NAME OF THE VETERINARY MEDICINAL PRODUCT</b>
--

LEUCOFELIGEN FeLV/RCP

<b>2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES</b>
---

102 µg FeLV  
1 ml

<b>3. BATCH NUMBER</b>
------------------------

Lot {number}

<b>4. EXPIRY DATE</b>
-----------------------

Exp. {mm/yyyy}

## **B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

### 1. Name of the veterinary medicinal product

LEUCOFELIGEN FeLV/RCP lyophilisate and suspension for suspension for injection for cats

### 2. Composition

Per dose of 1 ml:

Lyophilisate:

**Active substances:**

Live attenuated feline calicivirus (strain F9):	$10^{4.6}$ – $10^{6.1}$ CCID <sub>50</sub> *
Live attenuated feline viral rhinotracheitis virus (strain F2):	$10^{5.0}$ – $10^{6.6}$ CCID <sub>50</sub> *
Live attenuated feline panleucopenia virus (strain LR 72):	$10^{3.7}$ – $10^{4.5}$ CCID <sub>50</sub> *

\* Cell culture infectious dose 50%.

Suspension:

**Active substance:**

Minimum quantity of purified p45 FeLV-envelope antigen:	102 µg
---	--------

**Adjuvants:**

3% aluminium hydroxide gel expressed as mg Al <sup>3+</sup> :	1 mg
Purified extract of <i>Quillaja saponaria</i> :	10 µg

Lyophilisate: White color.

Suspension: Opalescent liquid.

### 3. Target species

Cats.

### 4. Indications for use

For active immunisation of cats from eight weeks of age against:

- feline calicivirosis to reduce clinical signs,
- feline viral rhinotracheitis to reduce clinical signs and viral excretion,
- feline panleucopenia to prevent leucopenia and to reduce clinical signs,
- feline leukaemia to prevent persistent viraemia and clinical signs of the related disease.

Onset of immunity:

- 3 weeks after the first injection of primary vaccination for the calicivirus component
- 3 weeks after the primary vaccination for the panleucopenia and leukaemia components
- 4 weeks after the primary vaccination for the rhinotracheitis virus components.

Duration of immunity:

After the primary vaccination course, the duration of immunity lasts for one year for all components.

Following a first booster vaccination one year after the primary vaccination course, a duration of immunity of 3 years has been demonstrated for the leukaemia component.



## **5. Contraindications**

None.

## **6. Special warnings**

### Special warnings:

Vaccinate healthy animals only.

Maternally derived antibodies, especially those against feline panleucopenia virus, can negatively influence the immune response to vaccination.

### Special precautions for safe use in the target species:

De-worming at least 10 days prior to vaccination is recommended.

Only feline leukaemia virus (FeLV) negative cats should be vaccinated. Therefore, a test for presence of FeLV before vaccination is recommended.

The feline calicivirus and feline panleucopenia virus vaccine strains can spread. It has been demonstrated that this spread did not cause adverse reactions on non-vaccinated cats.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

### Pregnancy and lactation:

Do not use in pregnant cats. The use is not recommended during lactation.

### Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

### Overdose:

No adverse reactions were observed after an overdose administration (10 doses of lyophilisate and 2 doses of suspension) of the veterinary medicinal product other than those mentioned in section “adverse events” except local reactions that can last longer (from 5 to 6 weeks at the most).

### Major incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

## **7. Adverse events**

Cats:

Common (1 to 10 animals / 100 animals treated):
Injection site reaction <sup>1</sup> , Injection site swelling <sup>1</sup> Injection site oedema <sup>1</sup> , Injection site nodule <sup>1</sup> Hyperthermia (Elevated temperature) <sup>2,3</sup> , Apathy <sup>3</sup> Digestive tract disorder <sup>3</sup>
Rare (1 to 10 animals / 10,000 animals treated):

Injection site pain <sup>4,5</sup> Sneezing <sup>5</sup> Conjunctivitis <sup>5</sup>
Very rare (<1 animal / 10,000 animals treated, including isolated reports):
Anaphylaxis <sup>6</sup> (severe allergic reaction) Febrile limping syndrome reactions <sup>7</sup>

<sup>1</sup>A moderate and transient local reaction ( $\leq 2$  cm) is observed after the first injection and resolves spontaneously within 3 to 4 weeks at the most. After the second injection, and subsequent administrations, this reaction is markedly reduced.

<sup>2</sup>Lasting 1 to 4 days.

<sup>3</sup>Transient signs.

<sup>4</sup>At palpation.

<sup>5</sup>This resolves without any treatment.

<sup>6</sup>In case of anaphylactic shock, appropriate symptomatic treatment should be administered.

<sup>7</sup>May occur very rarely in kittens, as reported in the literature after the use of any vaccine containing a feline calicivirus component

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

## **8. Dosage for each species, routes and method of administration**

Subcutaneous use (under the skin).

Administer subcutaneously one dose (1 ml) of the veterinary medicinal product according to the following regimen of vaccination.

### Primary vaccination:

- first injection in kittens from 8 weeks of age
- second injection 3 or 4 weeks later.

Maternally derived antibodies, especially those against feline panleucopenia virus, can negatively influence the immune response to vaccination. In such cases where maternally derived antibodies are expected, a third injection may be appropriate from 15 weeks of age.

### Re-vaccinations:

Following a first booster vaccination one year after the primary vaccination course, subsequent vaccinations can be performed at intervals of three years for the leukaemia component.

In this case, since annual revaccination is required for calicivirus, rhinotracheitis virus and panleucopenia virus components, a single dose of FELIGEN RCP can be used annually.

The vaccine can be used as a booster for kittens or cats previously vaccinated with FELIGEN RCP and LEUCOGEN separately.

## **9. Advice on correct administration**

Reconstitute one dose of lyophilisate with one dose (1ml) of suspension, shake gently and administer immediately.

**10. Withdrawal periods**

Not applicable.

**11. Special storage precautions**

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze.

Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after reconstitution according to directions: use immediately.

**12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment

Ask your veterinary surgeon how to dispose of medicines no longer required.

**13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

**14. Marketing authorisation numbers and pack sizes**

EU/2/09/097/001–002

Plastic or cardboard box of 10 lyophilisate vials and 10 suspension vials.

Plastic or cardboard box of 50 lyophilisate vials and 50 suspension vials.

Not all pack sizes may be marketed.

**15. Date on which the package leaflet was last revised**

{MM/YYYY}

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

**16. Contact details**

Marketing authorisation holder and manufacturer responsible for the batch release:

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
06516 Carros  
FRANCE

Local representatives and contact details to report suspected adverse reactions:

**België/Belgique/Belgien**  
VIRBAC BELGIUM NV  
Esperantolaan 4  
BE-3001 Leuven  
Tél/Tel : +32-(0)16 387 260  
phv@virbac.be

**Република България**  
ЕРГОН МИЛАНОВА ЕООД  
с. Бърложница 2222, Софийска област  
Република България  
Тел: + 359 359888215520  
ergonood@gmail.com

**Česká republika**  
VIRBAC Czech Republic, s.r.o.  
Žitavského 496  
156 00 Praha 5  
Tel.: +420 608 836 529

**Danmark**  
VIRBAC Danmark A/S  
Profilvej 1  
DK-6000 Kolding  
Tlf: +45 75521244  
virbac@virbac.dk

**Deutschland**  
VIRBAC Tierarzneimittel GmbH  
Rögen 20  
DE-23843 Bad Oldesloe  
Tel: +49-(4531) 805 111

**Eesti**  
OÜ ZOOVETVARU  
Uusaru 5  
EE-76505 Saue/Harjumaa  
Eesti  
Tel: + 372 56480207  
pv@zoovet.eu

**Lietuva**  
OÜ ZOOVETVARU  
Uusaru 5  
EE-76505 Saue/Harjumaa  
Eesti  
Tel: + 372 56480207  
pv@zoovet.eu

**Luxembourg/Luxemburg**  
VIRBAC BELGIUM NV  
Esperantolaan 4  
BE-3001 Leuven  
Belgique / Belgien  
Tél/Tel: +32-(0)16 387 260  
phv@virbac.be

**Magyarország**  
VIRBAC HUNGARY KFT  
Váci utca 81. 4 emelet.  
HU-1056 Budapest  
Tel: +36703387177  
akos.csoman@virbac.hu

**Malta**  
VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Franza  
Tel: + 33-(0)4 92 08 73 00

**Nederland**  
VIRBAC Nederland BV  
Hermesweg 15  
3771 ND-Barneveld  
Tel : +31-(0)342 427 127  
phv@virbac.nl

**Norge**  
VIRBAC  
13<sup>e</sup> rue LID  
FR-06517 Carros  
Tél : +33-(0)805 05 55 55

**Ελλάδα**

VIRBAC ΕΛΛΑΣ ΜΟΝΟΠΡΟΣΩΠΗ Α.Ε.  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμίας  
EL-14452, Μεταμόρφωση  
Τηλ: +30 2106219520  
info@virbac.gr

**España**

VIRBAC ESPAÑA SA  
Angel Guimerá 179-181  
ES-08950 Esplugues de Llobregat (Barcelona)  
Tel. : + 34-(0)93 470 79 40

**France**

VIRBAC France  
13<sup>e</sup> rue LID  
FR-06517 Carros  
Tél : +33-(0)805 05 55 55

**Hrvatska**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Francuska  
Tel: + 33-(0)4 92 08 73 00

**Ireland**

VIRBAC IRELAND  
McInerney & Saunders  
38, Main Street Swords, Co Dublin  
K67E0A2  
Republic Of Ireland  
Tel: +44 (0)-1359 243243

**Ísland**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Frakkland  
Sími: + 33-(0)4 92 08 73 00

**Italia**

VIRBAC SRL  
Via Ettore Bugatti, 15  
IT-20142 Milano  
Tel: + 39 02 40 92 47 1

**Κύπρος**

ΕΛΛΑΣ ΜΟΝΟΠΡΟΣΩΠΗ Α.Ε.  
13<sup>ο</sup> χλμ Ε.Ο. Αθηνών - Λαμίας  
EL-14452, Μεταμόρφωση  
Τηλ.: +30 2106219520  
info@virbac.gr

**Österreich**

VIRBAC Österreich GmbH  
Hildebrandgasse 27  
A-1180 Wien  
Tel: +43-(0)1-218 34 26-0

**Polska**

VIRBAC Sp. z o.o.  
ul. Puławska 314  
PL 02-819 Warszawa  
Tel.: + 48 22 855 40 46

**Portugal**

VIRBAC de Portugal Laboratórios, Lda.  
Rua do Centro Empresarial  
Edif.13 - Piso 1 - Escrit.3  
Quinta da Beloura  
2710-693 Sintra (Portugal)  
Tel: + 351 219 245 020

**România**

Altius SA  
Str. Zăgazului nr. 21-25, Corp A, et 8 si 8A  
Ap. A.8.2, sect 1,  
București, Romania  
Tel: + 40 021 310 88 80

**Slovenija**

VIRBAC  
1<sup>ère</sup> avenue 2065 m LID  
FR-06516 Carros  
Francija  
Tel : + 33-(0)4 92 08 73 00

**Slovenská republika**

VIRBAC Czech Republic, s.r.o.  
Žitavského 496  
156 00 Praha 5  
Tel.: +420 608 836 529

**Suomi/Finland**

BIOFARM OY  
Yrittäjäntie 20  
FI-03600 Karkkila  
Puh: +358-9-225 2560  
haittavaikutukset@biofarm.fi

**Sverige**

VIRBAC  
13<sup>e</sup> rue LID  
FR-06517 Carros  
Tél : +33-(0)805 05 55 55

**Latvija**  
OÜ ZOOVETVARU  
Uusaru 5  
EE-76505 Saue/Harjumaa  
Eesti  
Tel: + 372 56480207  
pv@zoovet.eu

**United Kingdom (Northern Ireland)**  
VIRBAC IRELAND  
McInerney & Saunders  
38, Main Street Swords, Co Dublin  
K67E0A2  
Republic Of Ireland  
Tel: +44 (0)-1359 243243

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

## **17. Other information**

For the leukaemia component, protection against persistent viraemia is observed in 73% of cats 3 weeks after their first vaccine injection.